杨邵瑜,陈雪琴,余捷凯,马胜林,潘月龙

• 1:杭州市第一人民医院肿瘤内科
• 2:浙江大学肿瘤研究所

摘要(Abstract)：

目的通过检测吉西他滨联合顺铂方案化疗敏感及耐药的晚期非小细胞肺癌患者治疗前血清蛋白质谱的差异,寻找可能的化疗耐药血清预测因子。方法收集非小细胞肺癌(non-small cell lung cancer,NSCLC)Ⅳ期患者治疗前血清,予以吉西他滨联合顺铂化疗,每2疗程后评估疗效。基质辅助激光解析电离化飞行时间质谱(matrix-assisted laser desorption/ionization-time of flight-mass spectrometry,MALDI-TOF-MS)检测血清蛋白,生物信息学分析找出差异蛋白峰,对筛选的差异蛋白峰进一步用遗传算法结合支持向量机模型的方法筛选最佳模型。结果收集25例晚期NSCLC患者,14例部分缓解(partial response,PR)进入化疗敏感组,2例疾病稳定(stable disease,SD)和9例出现疾病进展(progression disease,PD)进入化疗耐药组。化疗敏感组与耐药组出现10个明显差异蛋白质峰(P<0.05)。其中筛选得到4 978 Da、2 999 Da、4 996 Da、2 627 Da、4 188 Da、1 458 Da及1 984 Da 7个蛋白峰组成的最佳模型。结论 MALDI-TOF-MS技术检测得到血清差异蛋白模型可用于预测吉西他滨联合铂类二药化疗疗效。但需进一步扩大样本量以完善及验证疗效预测模型。

关键词(KeyWords)： 癌,非小细胞肺/药物疗法;抗肿瘤联合化疗方案;光谱法,质量,基质辅助激光解吸电离;抗肿瘤药/治疗应用;蛋白质组学;治疗结果

Abstract:

Keywords:

基金项目(Foundation): 浙江省自然科学基金重点项目(LZ13H160001);; 杭州市卫生科技计划一般项目(2012A007)

作者(Author): 杨邵瑜,陈雪琴,余捷凯,马胜林,潘月龙

DOI: 10.13267/j.cnki.syzlzz.2014.06.007

参考文献(References)：

• [1]Rinaldi M,Cauchi C,Gridelli C.First line chemotherapy in advanced or metastatic NSCLC[J].Ann Onc,2006,17(5):64-67.
• [2]Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst,2000,92(3):205-216.
• [3]陈雪琴,杨邵瑜,李鑫,等.蛋白指纹图谱技术筛选NSCLC患者EGFR-TKI疗效相关血清标记物[J].浙江医学,2012,34(18):1487-1489.
• [4]Jia J,Wang W,Meng W,et al.Development of a multiplex autoantibody test for detection of lung cancer[J].PLo S One,2014,9(4):e95444.
• [5]Zhao W,Yang Z,Liu X,et al.Identification ofα1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis[J].J Int Med Res,2013,41(3):573-583.
• [6]Taguchi F,Solomon B,Gregorc V,et al.Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors:a multicohort cross-institutional study[J].J Natl Cancer Inst,2007,99(11):838-846.
• [7]杨学宁,吴一龙,张绪超,等.吉非替尼治疗前后肺腺癌患者血清蛋白质谱的变化[J].中国肺癌杂志,2009,12(7):765-769.
• [8]Han M,Dai J,Zhang Y,et al.Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer[J].Oncol Rep,2012,28(6):2233-2238.
• [9]Han M,Liu Q,Yu J,et al.Identification of candi Date molecular markers predicting chemotherapy resistance in non-small cell lung cancer[J].Clin Chem Lab Med,2010,48(6):863-867.
• [10]Murphy L,Henry M,Meleady P,et al.Proteomic investigation of taxol and taxoere resistance and invasiveness in a squamous lung carcinoma cell line[J].Biochim Biophys Acta,2008,1784(9):1184-1191.
• [11]Murphy L,Clyness M,Keenan J.Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a aquamous lung carcinoma[J].Anticancer Res,2007(3A):1277-1284.
• [12]Poon TC.Opportunities and limitations of SELDI-TOFMS in biomedical research:practical advices[J].Expert Rev Proteomics,2007,4(1):51-65.
• [13]Dudley E.MALDI profiling and applications in medicine[J].Adv Exp Med Biol,2014,806:33-58.
• [14]Albrethsen J.Reproducibility in protein profiling by MALDI-TOF mass spectrometry[J].Clin Chem,2007,53(5):852-858.